Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting

Daniel De Paula, M. Vitória L.B. Bentley, Ram I. Mahato

Research output: Contribution to journalReview article

180 Citations (Scopus)

Abstract

RNA interference (RNAi) is an evolutionarily conserved process by which double-stranded small interfering RNA (siRNA) induces sequence-specific, post-transcriptional gene silencing. Unlike other mRNA targeting strategies, RNAi takes advantage of the physiological gene silencing machinery. The potential use of siRNA as therapeutic agents has attracted great attention as a novel approach for treating severe and chronic diseases. RNAi can be achieved by either delivery of chemically synthesized siRNAs or endogenous expression of small hairpin RNA, siRNA, and microRNA (miRNA). However, the relatively high dose of siRNA required for gene silencing limits its therapeutic applications. This review discusses several strategies to improve therapeutic efficacy as well as to abrogate off-target effects and immunostimulation caused by siRNAs. There is an in-depth discussion on various issues related to the (1) mechanisms of RNAi, (2) methods of siRNA production, (3) barriers to RNAi-based therapies, (4) biodistribution, (5) design of siRNA molecules, (6) chemical modification and bioconjugation, (7) complex formation with lipids and polymers, (8) encapsulation into lipid particles, and (9) target specificity for enhanced therapeutic effectiveness. Published by Cold Spring Harbor Laboratory Press.

Original languageEnglish (US)
Pages (from-to)431-456
Number of pages26
JournalRNA
Volume13
Issue number4
DOIs
StatePublished - Apr 1 2007

Fingerprint

Small Interfering RNA
RNA Interference
Gene Silencing
Lipids
Therapeutics
Double-Stranded RNA
MicroRNAs
Immunization
Polymers
Chronic Disease
Messenger RNA

Keywords

  • Bioconjugation
  • Chemical modification
  • Complex formation
  • RNA interference
  • Small interfering RNA

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. / De Paula, Daniel; Bentley, M. Vitória L.B.; Mahato, Ram I.

In: RNA, Vol. 13, No. 4, 01.04.2007, p. 431-456.

Research output: Contribution to journalReview article

De Paula, Daniel ; Bentley, M. Vitória L.B. ; Mahato, Ram I. / Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. In: RNA. 2007 ; Vol. 13, No. 4. pp. 431-456.
@article{dc6d9bbd17f4428ba07126c2bd7ddcc2,
title = "Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting",
abstract = "RNA interference (RNAi) is an evolutionarily conserved process by which double-stranded small interfering RNA (siRNA) induces sequence-specific, post-transcriptional gene silencing. Unlike other mRNA targeting strategies, RNAi takes advantage of the physiological gene silencing machinery. The potential use of siRNA as therapeutic agents has attracted great attention as a novel approach for treating severe and chronic diseases. RNAi can be achieved by either delivery of chemically synthesized siRNAs or endogenous expression of small hairpin RNA, siRNA, and microRNA (miRNA). However, the relatively high dose of siRNA required for gene silencing limits its therapeutic applications. This review discusses several strategies to improve therapeutic efficacy as well as to abrogate off-target effects and immunostimulation caused by siRNAs. There is an in-depth discussion on various issues related to the (1) mechanisms of RNAi, (2) methods of siRNA production, (3) barriers to RNAi-based therapies, (4) biodistribution, (5) design of siRNA molecules, (6) chemical modification and bioconjugation, (7) complex formation with lipids and polymers, (8) encapsulation into lipid particles, and (9) target specificity for enhanced therapeutic effectiveness. Published by Cold Spring Harbor Laboratory Press.",
keywords = "Bioconjugation, Chemical modification, Complex formation, RNA interference, Small interfering RNA",
author = "{De Paula}, Daniel and Bentley, {M. Vit{\'o}ria L.B.} and Mahato, {Ram I.}",
year = "2007",
month = "4",
day = "1",
doi = "10.1261/rna.459807",
language = "English (US)",
volume = "13",
pages = "431--456",
journal = "RNA",
issn = "1355-8382",
publisher = "Cold Spring Harbor Laboratory Press",
number = "4",

}

TY - JOUR

T1 - Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting

AU - De Paula, Daniel

AU - Bentley, M. Vitória L.B.

AU - Mahato, Ram I.

PY - 2007/4/1

Y1 - 2007/4/1

N2 - RNA interference (RNAi) is an evolutionarily conserved process by which double-stranded small interfering RNA (siRNA) induces sequence-specific, post-transcriptional gene silencing. Unlike other mRNA targeting strategies, RNAi takes advantage of the physiological gene silencing machinery. The potential use of siRNA as therapeutic agents has attracted great attention as a novel approach for treating severe and chronic diseases. RNAi can be achieved by either delivery of chemically synthesized siRNAs or endogenous expression of small hairpin RNA, siRNA, and microRNA (miRNA). However, the relatively high dose of siRNA required for gene silencing limits its therapeutic applications. This review discusses several strategies to improve therapeutic efficacy as well as to abrogate off-target effects and immunostimulation caused by siRNAs. There is an in-depth discussion on various issues related to the (1) mechanisms of RNAi, (2) methods of siRNA production, (3) barriers to RNAi-based therapies, (4) biodistribution, (5) design of siRNA molecules, (6) chemical modification and bioconjugation, (7) complex formation with lipids and polymers, (8) encapsulation into lipid particles, and (9) target specificity for enhanced therapeutic effectiveness. Published by Cold Spring Harbor Laboratory Press.

AB - RNA interference (RNAi) is an evolutionarily conserved process by which double-stranded small interfering RNA (siRNA) induces sequence-specific, post-transcriptional gene silencing. Unlike other mRNA targeting strategies, RNAi takes advantage of the physiological gene silencing machinery. The potential use of siRNA as therapeutic agents has attracted great attention as a novel approach for treating severe and chronic diseases. RNAi can be achieved by either delivery of chemically synthesized siRNAs or endogenous expression of small hairpin RNA, siRNA, and microRNA (miRNA). However, the relatively high dose of siRNA required for gene silencing limits its therapeutic applications. This review discusses several strategies to improve therapeutic efficacy as well as to abrogate off-target effects and immunostimulation caused by siRNAs. There is an in-depth discussion on various issues related to the (1) mechanisms of RNAi, (2) methods of siRNA production, (3) barriers to RNAi-based therapies, (4) biodistribution, (5) design of siRNA molecules, (6) chemical modification and bioconjugation, (7) complex formation with lipids and polymers, (8) encapsulation into lipid particles, and (9) target specificity for enhanced therapeutic effectiveness. Published by Cold Spring Harbor Laboratory Press.

KW - Bioconjugation

KW - Chemical modification

KW - Complex formation

KW - RNA interference

KW - Small interfering RNA

UR - http://www.scopus.com/inward/record.url?scp=34047190259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047190259&partnerID=8YFLogxK

U2 - 10.1261/rna.459807

DO - 10.1261/rna.459807

M3 - Review article

C2 - 17329355

AN - SCOPUS:34047190259

VL - 13

SP - 431

EP - 456

JO - RNA

JF - RNA

SN - 1355-8382

IS - 4

ER -